Celiac Disease Presenting in a Community-Based Gastroenterology Practice: Obesity and Bone Disease Are Common

Roldan, Giovanni A.; Jamot, Sehrish; Kopec, Krzysztof; Charoen, Amber; Leffler, Daniel A.; Feller, Edward; Shah, Samir A.

doi:10.1007/s10620-022-07521-9

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 A recent metanalysis identifies that 30-60% of newly diagnosed patients with CD show low BMD and 18-35% osteoporosis, despite different definitions and methods might have been used among different studies, underlying that bone alterations are extremely frequent in CD. [22][23][24] Prevalence of CD in idiopathic osteoporotic fractures has been assessed in several studies. However, there is still lack of univocal conclusion: Stenson et al 25 found a 3.4% incidence of CD in osteoporotic patients compared to 0.2% among general population, while others found increased IgA EmA values in sera of osteoporotic patients but normal intestinal mucosa.…”

Section: Pathologic Bone Alterations In Celiac Diseasementioning

confidence: 99%

Osteoporosis in Celiac Disease: An Update

Lungaro¹,

Manza²,

Costanzini³

et al. 2022

Preprint

View full text Add to dashboard Cite

Celiac disease (CD) is an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. In addition to the typical gastrointestinal symptoms such as diarrhea, bloating, or chronic abdominal pain, CD may also present a wide spectrum of manifestations, including low bone mineral density (BMD) and osteoporosis. This review aims to describe the role of CD in the development of skeletal alterations, underlying important clinical aspects and therapeutic implications. The etiopathology of bone lesions in CD is multifactorial and their management is challenging. Here, we provide gastroenterologists and orthopedics with an up-to-date overview on the link between CD and osteoporosis to improve the management of the CD condition.

show abstract

Section: Pathologic Bone Alterations In Celiac Diseasementioning

confidence: 99%

Osteoporosis in Celiac Disease: An Update

Lungaro¹,

Manza²,

Costanzini³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Celiac disease in adult patients

Ciacci,

De Micco,

Di Stefano

et al. 2024

Pediatric and Adult Celiac Disease

View full text Add to dashboard Cite

Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet

Anazco,

Fansa,

Ghusn

et al. 2023

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Goals: We aim to describe the weight loss outcomes of patients with celiac disease (CeD) taking antiobesity medications (AOMs) and compare it with the weight loss outcomes of patients without CeD taking AOMs. Background: Increasing rates of obesity and obesity-associated comorbidities have been previously reported in patients with CeD on a gluten-free diet. The effectiveness of AOMs in this population has not been previously described. Methods: In our retrospective cohort study, we matched 39 patients with treated CeD to 78 patients without CeD based on sex and AOM. We assessed the weight loss outcomes at 3, 6, and 12 months after starting the AOM in both cohorts and analyzed if there was a differential response when comparing by type of AOM [injectable glucagon-like peptide 1 (GLP-1) receptor agonists vs. oral non-GLP-1 AOMs]. Results: Both cohorts had similar baseline demographic and anthropometric characteristics. At 12 months, the CeD cohort had a nonsignificantly inferior total body weight loss percentage compared with the cohort without CeD (6.5% vs. 9.5%, P=0.13). The CeD cohort had a similar proportion of patients achieving a total body weight loss percentage of ≥5% than the cohort without CeD (72.7% vs. 72.1%, P=1.00). No significant difference was observed when comparing the weight loss outcomes of injectables (GLP-1 receptor agonists) to oral AOMs. The proportion of patients reporting side effects was similar for both groups, regardless of the type of AOM. Conclusion: Patients with CeD taking AOMs had similar weight loss outcomes to patients without CeD. Hence, AOMs can be a safe and effective therapy for weight management in patients with CeD.

show abstract

Celiac Disease Presenting in a Community-Based Gastroenterology Practice: Obesity and Bone Disease Are Common

Cited by 5 publications

References 32 publications

Osteoporosis in Celiac Disease: An Update

Osteoporosis in Celiac Disease: An Update

Celiac disease in adult patients

Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet

Contact Info

Product

Resources

About